☆ 4.6 Letter

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy

BLOOD ADVANCES (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

Joanna Zurko et al.

Summary: Allogeneic hematopoietic cell transplantation (alloHCT) can be an effective treatment option for large B-cell lymphoma (LBCL) patients who have experienced treatment failure after chimeric antigen receptor T-cell therapy (CAR T). This study examined the safety, outcomes, and toxicities of alloHCT in LBCL patients following CAR T failure, and found that it can provide durable remissions in some patients. Factors such as fewer lines of intervening therapy and complete response at the time of alloHCT were associated with better outcomes.

HAEMATOLOGICA (2023)

Add to Collection

Article Hematology

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: survival update and new extension cohort data

Laurie H. Sehn et al.

Summary: Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on the results of the GO29365 study. The study reported updated results from the randomized arms and the extension cohort, showing that pola + BR is an effective treatment option with a well-characterized safety profile.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy

Sushanth Gouni et al.

Summary: This retrospective analysis examined the efficacy and progression of PV combination therapy in LBCL patients who relapsed or progressed after CAR-T cell therapy. The treatment achieved a favorable response in some patients, but the majority still experienced disease progression. Bone marrow involvement and elevated lactate dehydrogenase levels were associated with shorter progression-free survival.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

Paolo Strati et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 can lead to long-term adverse effects such as cytopenia and immune deficiency. Prolonged monitoring and prophylaxis against opportunistic infections are crucial to improve the long-term safety of this therapy.

HAEMATOLOGICA (2021)

Add to Collection

Article Hematology

Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation

Narendranath Epperla et al.

Summary: Reduced-intensity conditioning regimens are commonly used for allogeneic hematopoietic cell transplantation in patients with diffuse large B cell lymphoma. This study analyzed the outcomes of the three most commonly used RIC regimens in DLBCL patients, finding that Flu/Bu was the best choice for less fit or heavily pretreated patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Oncology

Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma

Solomon A. Graf et al.

Summary: This prospective study investigated the efficacy of ibrutinib monotherapy in 20 patients with histologically transformed diffuse large B-cell lymphoma, showing objective responses in 35% of patients with a median progression-free survival of 4.1 months. Ibrutinib demonstrated favorable tolerability and promising activity in this setting with limited treatment options, suggesting its potential utility as a bridge to more definitive treatments.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Letter Medicine, General & Internal

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

Elise A. Chong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi et al.

Summary: Loncastuximab tesirine shows substantial antitumor activity and acceptable safety profile in patients with relapsed or refractory DLBCL, potentially offering a new therapeutic option for heavily pretreated individuals.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases

Kristin Gerhardt et al.

Summary: The study reports two heavily pretreated patients with different types of lymphoma who relapsed after CAR T-cell therapy and achieved complete metabolic remission after Pola-BR therapy, followed by alloHSCT treatment and disease-free survival post-operation. The findings suggest that Pola-BR may be an effective bridging therapy before alloHSCT for patients relapsing after CAR T-cell therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

[Anonymous]

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Oncology

Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant

Nilanjan Ghosh et al.

JAMA ONCOLOGY (2020)

Add to Collection

Meeting Abstract Hematology

Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion

Catherine Thieblemont et al.

BLOOD (2020)

Add to Collection

Letter Hematology

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy

Victor A. Chow et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection

Article Hematology

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy

Mazyar Shadman et al.

BLOOD ADVANCES (2019)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.